<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">10222</article-id><article-id pub-id-type="doi">10.7554/eLife.10222</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-37989"><name><surname>Carelli</surname><given-names>Jordan D</given-names></name><aff><institution content-type="dept">Chemistry and Chemical Biology Graduate Program</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38712"><name><surname>Sethofer</surname><given-names>Steven G</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-46260"><name><surname>Smith</surname><given-names>Geoffrey A</given-names></name><aff><institution content-type="dept">Chemistry and Chemical Biology Graduate Program</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38713"><name><surname>Miller</surname><given-names>Howard R</given-names></name><aff><institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38714"><name><surname>Simard</surname><given-names>Jillian L</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38715"><name><surname>Merrick</surname><given-names>William C</given-names></name><aff><institution content-type="dept">Department of Biochemistry, School of Medicine</institution>, <institution>Case Western Reserve University</institution>, <addr-line><named-content content-type="city">Cleveland</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38716"><name><surname>Jain</surname><given-names>Rishi K</given-names></name><aff><institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-38717"><name><surname>Ross</surname><given-names>Nathan T</given-names></name><aff><institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-4277"><name><surname>Taunton</surname><given-names>Jack</given-names></name><aff><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country><email>jack.taunton@ucsf.edu</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1065"><name><surname>Cravatt</surname><given-names>Ben</given-names></name><role>Reviewing editor</role><aff><institution>The Scripps Research Institute</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>12</month><year>2015</year></pub-date><volume>4</volume><elocation-id>e10222</elocation-id><supplementary-material><ext-link xlink:href="elife-10222-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>20</day><month>07</month><year>2015</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>© 2015, Carelli et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Carelli et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose molecular mode of action was unknown. The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself. Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A∙GTP∙aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin. Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation. We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>